BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 12357362)

  • 1. Rituximab-based chemotherapy for steroid-refractory autoimmune hemolytic anemia of chronic lymphocytic leukemia.
    Gupta N; Kavuru S; Patel D; Janson D; Driscoll N; Ahmed S; Rai KR
    Leukemia; 2002 Oct; 16(10):2092-5. PubMed ID: 12357362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prompt and sustained response of a steroid-refractory autoimmune hemolytic anemia to a rituximab-based therapy in a chronic lymphocytic leukemia patient.
    Gentile M; Lucia E; Iorio C; Vigna E; Mazzone C; Morelli R; Bisconte MG; Gentile C; Morabito F
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):741-3. PubMed ID: 18064461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A combination of rituximab, cyclophosphamide and dexamethasone effectively treats immune cytopenias of chronic lymphocytic leukemia.
    Kaufman M; Limaye SA; Driscoll N; Johnson C; Caramanica A; Lebowicz Y; Patel D; Kohn N; Rai K
    Leuk Lymphoma; 2009 Jun; 50(6):892-9. PubMed ID: 19391041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
    D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
    Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of severe refractory autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab (humanized CD52 monoclonal antibody).
    Karlsson C; Hansson L; Celsing F; Lundin J
    Leukemia; 2007 Mar; 21(3):511-4. PubMed ID: 17215854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The successful treatment of refractory autoimmune hemolytic anemia with rituximab in a patient with chronic lymphocytic leukemia.
    Pamuk GE; Turgut B; Demir M; Tezcan F; Vural O
    Am J Hematol; 2006 Aug; 81(8):631-3. PubMed ID: 16906592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
    Borthakur G; O'Brien S; Wierda WG; Thomas DA; Cortes JE; Giles FJ; Kantarjian HM; Lerner S; Keating MJ
    Br J Haematol; 2007 Mar; 136(6):800-5. PubMed ID: 17341265
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Successful treatment with rituximab for autoimmune hemolytic anemia associated with chronic lymphocytic leukemia].
    Tanaka Y; Ito Y; Yoshizawa S; Fujimoto H; Gotoh M; Tauchi T; Kimura Y; Ohyashiki K
    Rinsho Ketsueki; 2013 Feb; 54(2):229-31. PubMed ID: 23470833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab-cyclophosphamide-dexamethasone combination in the management of autoimmune cytopenias associated with chronic lymphocytic leukemia.
    Rossignol J; Michallet AS; Oberic L; Picard M; Garon A; Willekens C; Dulery R; Leleu X; Cazin B; Ysebaert L
    Leukemia; 2011 Mar; 25(3):473-8. PubMed ID: 21127498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
    Quinquenel A; Willekens C; Dupuis J; Royer B; Ysebaert L; De Guibert S; Michallet AS; Feugier P; Guieze R; Levy V; Delmer A
    Am J Hematol; 2015 Mar; 90(3):204-7. PubMed ID: 25428829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab for warm-type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients.
    D'Arena G; Califano C; Annunziata M; Tartarone A; Capalbo S; Villani O; Amendola G; Pietrantuono G; Ferrara F; Pinto A; Musto P; D'Arco AM; Cascavilla N
    Eur J Haematol; 2007 Jul; 79(1):53-8. PubMed ID: 17532766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia.
    Smolej L; Doubek M; Panovská A; Simkovič M; Brychtová Y; Belada D; Motyčková M; Mayer J
    Leuk Res; 2012 Oct; 36(10):1278-82. PubMed ID: 22840362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intractable autoimmune hemolytic anemia in B cell chronic lymphocytic leukemia resolved by Rituximab.
    Shvidel L; Shtalrid M; Berrebi A
    Leuk Lymphoma; 2004 Jul; 45(7):1493-4. PubMed ID: 15359657
    [No Abstract]   [Full Text] [Related]  

  • 15. Rituximab-cyclophosphamide-dexamethasone combination in management of autoimmune cytopenias associated with chronic lymphocytic leukemia.
    Michallet AS; Rossignol J; Cazin B; Ysebaert L
    Leuk Lymphoma; 2011 Jul; 52(7):1401-3. PubMed ID: 21699387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.
    Nikitin E; Kislova M; Morozov D; Belyakova V; Suvorova A; Sveshnikova J; Vyscub G; Matveeva I; Shirokova M; Shipaeva A; Klitochenko T; Makarovskaya P; Dmitrieva E; Biderman B; Sudarikov A; Obukhova T; Samoilova O; Kaplanov K; Konstantinova T; Mayorova O; Poddubnaya I; Ptushkin V
    Leukemia; 2023 Jul; 37(7):1464-1473. PubMed ID: 37202442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia.
    Peñalver FJ; Alvarez-Larrán A; Díez-Martin JL; Gallur L; Jarque I; Caballero D; Díaz-Mediavilla J; Bustelos R; Fernández-Aceñero MJ; Cabrera JR;
    Ann Hematol; 2010 Nov; 89(11):1073-80. PubMed ID: 20526716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
    Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
    Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
    Osterborg A; Karlsson C; Lundin J
    Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
    Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
    J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.